We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery

This study is currently recruiting participants.
Verified January 2017 by W ten Hoope, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Sponsor:
ClinicalTrials.gov Identifier:
NCT02071433
First Posted: February 25, 2014
Last Update Posted: January 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
W ten Hoope, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  Purpose
The purpose of this study is to determine whether blockade of the saphenous nerve can provide the same degree of analgesia postoperatively for ACLS as a femoral nerve block without resulting motor blockade enhancing shortening of hospital stay en functional outcome.

Condition Intervention
Postoperative Analgesia for Anterior Cruciate Ligament Surgery of the Knee Procedure: Saphenous nerve blockade Procedure: Femoral nerve blockade

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery

Further study details as provided by W ten Hoope, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):

Primary Outcome Measures:
  • Readiness to discharge from day-care center in hours according to Post-Anesthetic Discharge Scoring System (PADSS).[ [ Time Frame: 1 day ]

Secondary Outcome Measures:
  • Motor block [ Time Frame: 2 days ]
  • Pain (VAS) [ Time Frame: 2 days ]
  • Sensory blockade extent [ Time Frame: 1 Day ]
  • Time to rescue analgesic and post operative opioid consumption [ Time Frame: 1 Day ]
  • Overall Benefit of Analgesia Score (OBAS) [ Time Frame: 6 weeks ]
  • SF-12 score [ Time Frame: 12 weeks ]
  • KOOS-score [ Time Frame: 12 weeks ]
  • IKDC-score [ Time Frame: 12 weeks ]

Estimated Enrollment: 58
Study Start Date: March 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Saphenous nerve blockade
Experimental treatment 15 mL of levobupivacaine 0.5%
Procedure: Saphenous nerve blockade
Active Comparator: Femoral nerve blockade
Standard treatment 15 mL of levobupivacaine 0.5%
Procedure: Femoral nerve blockade

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 18-65 years
  • ASA status I - III
  • rupture of the anterior cruciate ligament.

Exclusion Criteria:

  • contraindication for regional anesthesia
  • allergy against local anesthetics
  • BMI > 35
  • pre-existing diagnosed neuropathy of the operated leg
  • ingestion of strong opioids
  • pregnancy or breastfeeding status
  • History of significant cardiovascular disease (MI, CVA, peripheral vascular disease)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02071433


Contacts
Contact: Werner ten Hoope, MD 0031-205663633 w.tenhoope@amc.uva.nl
Contact: M.W. Hollmann, professor dr., MD 0031-205663633 m.w.hollmann@amc.uva.nl

Locations
Netherlands
Academic Medical Centre Amsterdam Recruiting
Amsterdam, Netherlands, 1105 AZ
Contact: M.W. Hollmanm       m.w.hollmann@amc.uva.nl   
Principal Investigator: Werner ten Hoope, MD         
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  More Information

Responsible Party: W ten Hoope, MD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT02071433     History of Changes
Other Study ID Numbers: ACLS
First Submitted: February 24, 2014
First Posted: February 25, 2014
Last Update Posted: January 26, 2017
Last Verified: January 2017

Keywords provided by W ten Hoope, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
Saphenous nerve block
Adductor canal block
Anterior cruciate ligament
Pain management
Day care

Additional relevant MeSH terms:
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs